Development of a robust luciferase reporter 1b/2a hepatitis C virus (HCV) for characterization of early stage HCV life cycle inhibitors

Antiviral Research

Volumn 98, Issue 1, 2013, Pages 85-92

  Chan, Katie ^a   Robinson, Margaret ^a   Yang, Huiling ^a   Cornew, Sophia ^a   Delaney IV, William E ^a  

^a GILEAD SCIENCES   (United States)

Author keywords

Adaptive mutations; Con1; HCVcc; JFH1; Luciferase reporter; Virus production

Indexed keywords

LUCIFERASE; LUCIFERASE RECEPTOR 1B; LUCIFERASE RECEPTOR 2A; UNCLASSIFIED DRUG;

ADAPTATION; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; GENE MUTATION; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; LIFE CYCLE; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE; VIRUS GENOME; VIRUS LOAD;

ANTIVIRAL AGENTS; CELL LINE, TUMOR; DRUG EVALUATION, PRECLINICAL; GENES, REPORTER; HEPACIVIRUS; HEPATITIS C; HUMANS; LUCIFERASES, RENILLA; VIRUS REPLICATION;

HEPATITIS C VIRUS; RENILLA LUCIFERASE;

EID: 84874930727     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2013.01.005     Document Type: Article

References (25)

1. Baldick C.J., Wichroski M.J., Pendri A., Walsh A.W., Fang J., Mazzucco C.E., Pokornowski K.A., Rose R.E., Eggers B.J., Hsu M., Zhai W., Zhai G., Gerritz S.W., Poss M.A., Meanwell N.A., Cockett M.I., Tenney D.J. A novel small molecule inhibitor of hepatitis C virus entry. PLoS Pathogens 2010, 6:e1001086.
2. Burney T., Dusheiko G. Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients. Expert Review of Anti-infective Therapy 2011, 9:151-160.
3. Chan K., Cheng G., Beran R.K., Yang H., Appleby T.C., Pokrovskii M.V., Mo H., Zhong W., Delaney W.E. An adaptive mutation in NS2 is essential for efficient production of infectious 1b/2a chimeric hepatitis C virus in cell culture. Virology 2012, 422:224-234.
4. Chen S.H., Tan S.L. Discovery of small-molecule inhibitors of HCV NS3-4A protease as potential therapeutic agents against HCV infection. Current Medicinal Chemistry 2005, 12:2317-2342.
5. Friebe P., Boudet J., Simorre J.P., Bartenschlager R. Kissing-loop interaction in the 3'end of the hepatitis C virus genome essential for RNA replication. Journal of Virology 2005, 79:380-392.
6. Gentzsch J., Hinkelmann B., Kaderali L., Irschik H., Jansen R., Sasse F., Frank R., Pietschmann T. Hepatitis C virus complete life cycle screen for identification of small molecules with pro- or antiviral activity. Antiviral Research 2011, 89:136-148.
7. Gottwein J.M., Scheel T.K., Hoegh A.M., Lademann J.B., Eugen-Olsen J., Lisby G., Bukh J. Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a/2a (S52/JFH1) viruses. Gastroenterology 2007, 133:1614-1626.
8. Gottwein J.M., Scheel T.K., Jensen T.B., Lademann J.B., Prentoe J.C., Knudsen M.L., Hoegh A.M., Bukh J. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology (Baltimore, Md.) 2009, 49:364-377.
9. Gravitz L. Introduction: a smouldering public-health crisis. Nature 2011, 474:S2-S4.
10. Hiraga N., Imamura M., Abe H., Hayes C.N., Kono T., Onishi M., Tsuge M., Takahashi S., Ochi H., Iwao E., Kamiya N., Yamada I., Tateno C., Yoshizato K., Matsui H., Kanai A., Inaba T., Tanaka S., Chayama K. Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo. Hepatology (Baltimore, Md.) 2011, 54:781-788.
11. Jones C.T., Murray C.L., Eastman D.K., Tassello J., Rice C.M. Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. Journal of Virology 2007, 81:8374-8383.
12. Koutsoudakis G., Kaul A., Steinmann E., Kallis S., Lohmann V., Pietschmann T., Bartenschlager R. Characterization of the early steps of hepatitis C virus infection by using luciferase reporter viruses. Journal of Virology 2006, 80:5308-5320.
13. Pawlotsky J.M. The invaders and the barrier. Journal of Hepatology 2012, 56:11-13.
14. Pietschmann T., Kaul A., Koutsoudakis G., Shavinskaya A., Kallis S., Steinmann E., Abid K., Negro F., Dreux M., Cosset F.L., Bartenschlager R. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:7408-7413.
15. Reed L.J., Muench H. A simple method of estimating 50 per cent end-points. Am. J. Hyg. 1938, 27:493-497.
16. Samuel C.E. Adenosine deaminases acting on RNA (ADARs) are both antiviral and proviral. Virology 2011, 411:180-193.
17. Scheel T.K., Gottwein J.M., Carlsen T.H., Li Y.P., Jensen T.B., Spengler U., Weis N., Bukh J. Efficient culture adaptation of hepatitis C virus recombinants with genotype-specific core-NS2 by using previously identified mutations. Journal of Virology 2011, 85:2891-2906.
18. Scheel T.K., Gottwein J.M., Jensen T.B., Prentoe J.C., Hoegh A.M., Alter H.J., Eugen-Olsen J., Bukh J. Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. Proceedings of the National Academy of Sciences of the United States of America 2008, 105:997-1002.
19. Schlutter J. Therapeutics: new drugs hit the target. Nature 2011, 474:S5-7.
20. Schmitt M., Scrima N., Radujkovic D., Caillet-Saguy C., Simister P.C., Friebe P., Wicht O., Klein R., Bartenschlager R., Lohmann V., Bressanelli S. A comprehensive structure-function comparison of hepatitis C virus strain JFH1 and J6 polymerases reveals a key residue stimulating replication in cell culture across genotypes. Journal of Virology 2011, 85:2565-2581.
21. Susser S., Welsch C., Wang Y., Zettler M., Domingues F.S., Karey U., Hughes E., Ralston R., Tong X., Herrmann E., Zeuzem S., Sarrazin C. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology (Baltimore, Md.) 2009, 50:1709-1718.
22. Taylor D.R., Puig M., Darnell M.E., Mihalik K., Feinstone S.M. New antiviral pathway that mediates hepatitis C virus replicon interferon sensitivity through ADAR1. Journal of Virology 2005, 79:6291-6298.
23. Welzel T.M., Morgan T.R., Bonkovsky H.L., Naishadham D., Pfeiffer R.M., Wright E.C., Hutchinson A.A., Crenshaw A.T., Bashirova A., Carrington M., Dotrang M., Sterling R.K., Lindsay K.L., Fontana R.J., Lee W.M., Di Bisceglie A.M., Ghany M.G., Gretch D.R., Chanock S.J., Chung R.T., O'Brien T.R., Group, H.-C.T. Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. Hepatology (Baltimore, Md.) 2009, 49:1847-1858.
24. Yi M., Ma Y., Yates J., Lemon S.M. Compensatory mutations in E1, p7, NS2, and NS3 enhance yields of cell culture-infectious intergenotypic chimeric hepatitis C virus. Journal of Virology 2007, 81:629-638.
25. Zhang Y., Weady P., Duggal R., Hao W. Novel chimeric genotype 1b/2a hepatitis C virus suitable for high-throughput screening. Antimicrobial Agents and Chemotherapy 2008, 52:666-674.